MiRNA as potential biomarkers of breast cancer in the lebanese population and in young women: A pilot study

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Nassar, Farah J ^a   Sabban, Maya El ^a   Zgheib, Nathalie K ^a   Tfayli, Arafat ^a   Boulos, Fouad ^a   Jabbour, Mark ^a   El Saghir, Nagi S ^a   Talhouk, Rabih ^a   Bazarbachi, Ali ^a   Calin, George A ^b   Nasr, Rihab ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; MICRORNA 10B; MICRORNA 148B; MICRORNA 155; MICRORNA 21; MICRORNA 221; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; GENETIC MARKER; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEBANESE; MAJOR CLINICAL STUDY; PILOT STUDY; POSTMENOPAUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; BIOSYNTHESIS; BREAST; BREAST NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; LEBANON; PATHOLOGY;

ADULT; BREAST; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; LEBANON; MICRORNAS; PILOT PROJECTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84907187956     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107566     Document Type: Article

References (35)

1. El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, et al. (2007) Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 5: 225-233.
2. Shamseddine A, Musallam K (2010) Cancer Epidemiology in Lebanon. Middle East Journal of Cancer 1: 41-44.
3. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, et al. (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6: 194.
4. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854.
5. Ha TY (2011) MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw 11: 135-154.
6. Li Y, Kowdley KV (2012) MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics 10: 246-253.
7. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
8. Li L, Xiao B, Tong H, Xie F, Zhang Z, et al. (2012) Regulation of breast cancer tumorigenesis and metastasis by miRNAs. Expert Rev Proteomics 9: 615-625.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
10. Chen WX, Hu Q, Qiu MT, Zhong SL, Xu JJ, et al. (2013) miR-221/222: promising biomarkers for breast cancer. Tumour Biol 34: 1361-1370.
11. Ma L (2010) Role of miR-10b in breast cancer metastasis. Breast Cancer Res 12: 210.
12. Mattiske S, Suetani RJ, Neilsen PM, Callen DF (2012) The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev 21: 1236-1243.
13. Singh R, Mo YY (2013) Role of microRNAs in breast cancer. Cancer Biol Ther 14: 201-212.
14. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, et al. (2013) Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 132: 1602-1612.
15. Zgheib NK, Shamseddine AA, Geryess E, Tfayli A, Bazarbachi A, et al. (2013) Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. Mutat Res 747-748: 40-47.
16. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43.
17. Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56: 37-47; quiz 50-31.
18. Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, et al. (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5: S2-8.
19. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, et al. (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324-3330.
20. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, et al. (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18: 1341-1351.
21. Han M, Liu M, Wang Y, Chen X, Xu J, et al. (2012) Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 7: e39520.
22. Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336.
23. Zhu S, Wu H, Wu F, Nie D, Sheng S, et al. (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359.
24. Jiang S, Zhang HW, Lu MH, He XH, Li Y, et al. (2010) MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70: 3119-3127.
25. Kong W, He L, Coppola M, Guo J, Esposito NN, et al. (2010) MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285: 17869-17879.
26. Cimino D, De Pitta C, Orso F, Zampini M, Casara S, et al. (2013) miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. Faseb j 27: 1223-1235.
27. Chang H, Zhou X, Wang ZN, Song YX, Zhao F, et al. (2012) Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Mol Med Rep 5: 1277-1280.
28. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688.
29. Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, et al. (2013) MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer.
30. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, et al. (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 5: e13735.
31. Lu Z, Ye Y, Jiao D, Qiao J, Cui S, et al. (2012) miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol Lett 4: 1027-1032.
32. Song CG, Wu XY, Fu FM, Han ZH, Wang C, et al. (2012) [Correlation of miR-155 on formalin-fixed paraffin embedded tissues with invasiveness and prognosis of breast cancer]. Zhonghua Wai Ke Za Zhi 50: 1011-1014.
33. Qian B, Katsaros D, Lu L, Preti M, Durando A, et al. (2009) High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 117: 131-140.
34. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, et al. (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna 14: 2348-2360.
35. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, et al. (2013) Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat 137: 579-587.